Key Takeaways
- Matica Biotechnology positions South Korea as a prime location for investigator-initiated trials (IITs) by combining manufacturing, clinical, and regulatory support.
- The upcoming webinar will compare Korea’s advantages in IITs against China, Australia, and Europe, focusing on multiple development criteria.
- The integrated platform aims to streamline operations, reduce project management burdens, and encourage global biotech firms to enter the Korean market.
Korea as a Hub for Investigator-Initiated Trials
Matica Biotechnology is working to establish South Korea as a strategic location for investigator-initiated trials (IITs), aligning with a trend of global drugmakers diversifying away from China due to geopolitical tensions. As part of this initiative, the company is offering an integrated platform that combines manufacturing, clinical development, and regulatory support.
On Tuesday, Matica Biotechnology, a subsidiary of Korea’s Cha Biotech, will host an online seminar titled “South Korea IIT: The Emerging Global Alternative for Accelerating Cell & Gene Therapy Development.” The seminar aims to showcase Korea’s strengths compared to China, Australia, and Europe, focusing on six criteria: development speed, data quality, integration of manufacturing and clinical processes, regulatory readiness, supply chain stability, and long-term commercialization potential.
Cha Biotech emphasizes that Korea’s integrated ecosystem includes world-class hospitals, GMP-certified facilities, and recognized regulatory standards. The webinar will encourage biotechnology companies to assess IIT strategies based on various development factors rather than solely on cost. Each region offers unique advantages, and geographic selection should be approached strategically.
In June, Cha Biotech and Matica launched the “Accelerated Matica Korea IIT Integrated Platform Solution.” This initiative provides overseas biotechnology firms with a centralized point of contact to facilitate IITs in Korea by merging manufacturing, clinical operations, hospital networks, and regulatory support. This integrated approach is designed to alleviate project management challenges, expedite development timelines, and enhance the efficiency of clinical strategies.
Moreover, Matica’s US-based GMP facility plays a crucial role in safeguarding clients’ intellectual property while allowing for quicker generation of high-quality clinical data. A Cha Biotech official remarked that the Matica K-IIT Program aims to bolster international biotech companies in entering Korea and reinforces the country’s emergence as a leading clinical development hub for advanced therapies in Asia.
The content above is a summary. For more details, see the source article.